Tributyrin in Inflammation: Does White Adipose Tissue Affect Colorectal Cancer?
Luana Amorim BiondoAlexandre Abilio S TeixeiraLoreana Sanches SilveiraCamila O SouzaRaquel G F CostaTiego Aparecido DinizFrancielle C MoseleJose Cesar Rosa NetoPublished in: Nutrients (2019)
Colorectal cancer affects the large intestine, leading to loss of white adipose tissue (WAT) and alterations in adipokine secretion. Lower incidence of colorectal cancer is associated with increased fibre intake. Fructooligosaccharides (FOS) are fibres that increase production of butyrate by the intestinal microbiota. Tributyrin, a prodrug of butyric acid, exerts beneficial anti-inflammatory effects on colorectal cancer. Our aim was to characterise the effects of diets rich in FOS and tributyrin within the context of a colon carcinogenesis model, and characterise possible support of tumorigenesis by WAT. C57/BL6 male mice were divided into four groups: a control group (CT) fed with chow diet and three colon carcinogenesis-induced groups fed either with chow diet (CA), tributyrin-supplemented diet (BUT), or with FOS-supplemented diet. Colon carcinogenesis decreased adipose mass in subcutaneous, epididymal, and retroperitoneal tissues, while also reducing serum glucose and leptin concentrations. However, it did not alter the concentrations of adiponectin, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF)-α in WAT. Additionally, the supplements did not revert the colon cancer affected parameters. The BUT group exhibited even higher glucose tolerance and levels of IL-6, VEGF, and TNF-α in WAT. To conclude our study, FOS and butyrate supplements were not beneficial. In addition, butyrate worsened adipose tissue inflammation.
Keyphrases
- adipose tissue
- weight loss
- insulin resistance
- physical activity
- high fat diet
- oxidative stress
- rheumatoid arthritis
- anti inflammatory
- metabolic syndrome
- computed tomography
- gene expression
- endothelial cells
- magnetic resonance imaging
- high glucose
- cancer therapy
- drug delivery
- skeletal muscle
- blood pressure
- minimally invasive
- drug release